2016 Genitourinary Cancers Symposium

prostate cancer

Hypofractionation Is Ready for Prime Time in Prostate Cancer, but Will It Be Adopted?

Separate phase III trials presented at the 2016 Genitourinary Cancers Symposium demonstrated that modest hypofractionated radiotherapy is noninferior to conventional radiotherapy for men with intermed...

bladder cancer

Adjuvant Chemoradiotherapy in Locally Advanced Bladder Cancer: Hint of Benefit That Needs Confirmation

Adjuvant sequential chemotherapy plus radiation therapy and adjuvant radiation therapy alone significantly improved local tumor control compared with adjuvant chemotherapy alone in locally advanced bl...

Kidney Cancer

Genomic, Molecular Differences in Tumor Biology May Explain Inferior Survival in African Americans With Kidney Cancer

African Americans who develop metastatic renal cell carcinoma have had worse survival historically than whites. With the advent of targeted therapy, the hope is that the gap in survival would be narro...

prostate cancer

Active Holistic Surveillance May Prevent Unnecessary Biopsies in Low- and Low/Intermediate-Risk Prostate Cancer

The use of prostate-specific antigen (PSA) screening has led to a dramatic rise in the number of men diagnosed with low-grade prostate cancer. Active surveillance is recommended to manage patients wit...

prostate cancer

New Technology to Characterize Circulating Tumor Cells Suggests Better Treatment Decision-Making in Prostate Cancer

An early study showed that an experimental blood test (ie, “liquid biopsy”) that characterizes the phenotype and genomic characteristics of circulating tumor cells appears to have utility in personali...

solid tumors

Atezolizumab in Urothelial Cancer: Ushering in a New Standard of Care

Atezolizumab achieved excellent results in a cohort of patients with platinum-resistant urothelial cancer enrolled in a large phase II trial known as IMvigor 210.1 Overall response rates were greatly ...

solid tumors

Improved Outcomes in Patients With Germ Cell Testicular Tumors in the Modern Era

Although patients with poor-risk metastatic testicular germ cell tumors continue to have less favorable outcomes, the bar has been raised by contemporary treatment. There is still room for improvement...

kidney cancer

Two Contenders for Second-Line Treatment of Advanced Renal Cell Carcinoma

Options for second-line therapy of advanced/metastatic renal cell carcinoma are expanding. Updates from the CheckMate 025 and METEOR ­trials presented at the 2016 Genitourinary Cancers Symposium solid...

prostate cancer

Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use

Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer ...

solid tumors

Christopher J. Sweeney, MBBS: Testicular Cancer Update

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, an...

prostate cancer

Maha Hussain, MD, on Prostate Cancer: Keynote Lecture

Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.

prostate cancer

W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).

solid tumors

Nicholas D. James, BSc, MBBS, PhD, on Urothelial Carcinomas: Year in Review

Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.

prostate cancer

Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and after salvage radiati...

bladder cancer

Srikala S. Sridhar, MD: Bladder Cancer Update

Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review (French Language Version)

Fred Saad, MD, of the University of Montreal, summarizes in French his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease.

prostate cancer

Fred Saad, MD, on Prostate Cancer: The Year in Review

Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see th...

kidney cancer

Toni Choueiri, MD: Renal Cancer Update

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its im...

kidney cancer

Hans-Joerg Hammers, MD, PhD, on Renal Cancer: Using Immune Checkpoint Blockers in the Clinic

Hans-Joerg Hammers, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes this keynote lecture on kidney cancer, which included discussion of the current role of PD-1 ...

solid tumors

Bishoy M. Faltas, MD, on Advanced Urothelial Carcinoma: Generating a Neoantigen Map

Bishoy M. Faltas, MD, of Weill Cornell Medical College, discusses his team’s work using whole exome sequencing, which may have important implications for selecting patients for immunotherapeutic appro...

solid tumors

Dean F. Bajorin, MD, on Rare Urinary Tract Cancers: Expert Perspectives on Treatment

Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.

prostate cancer

David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial

David P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).

kidney cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial (French Language Version)

Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses in French a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (A...

kidney cancer

Bernard J. Escudier, MD, on Renal Cell Carcinoma: Results From the METEOR Trial

Bernard J. Escudier, MD, of the Institut Gustave Roussy, discusses a subgroup analyses of this phase III study of cabozantinib vs everolimus in patients with advanced renal cell carcinoma (Abstract 49...

solid tumors

Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update

Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.

prostate cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanc...

prostate cancer

Even After Antiandrogen Therapy, Docetaxel Remains Useful in Prostate Cancer

A study presented at the 2016 Genitourinary Cancers Symposium showed that 40% of patients with metastatic castration-resistant prostate cancer treated with docetaxel following abiraterone (Zytiga) had...

issues in oncology

Patient-Centric Care: Translating Research to Results

The 2016 Genitourinary Cancers Symposium was held earlier this month in San Francisco. Abstracts and presentations included data and discussion on the latest strategies in the prevention, screening, d...

Advertisement

Advertisement



Advertisement